×
About 1,957 results

ALLMedicine™ Cardiovascular Risk Reduction Center

Research & Reviews  857 results

Clinical and metabolomic predictors of regression to normoglycemia in a population at i...
https://doi.org/10.1186/s12933-021-01246-1 10.1016/j.diabres.2018.02.023 10.1097/MCO.0000000000000307 10.1136/bmj.i5953 10.1056/NEJM199807233390404 10.1016/S0140-6736(10)60484-9 10.1016/S0140-6736(98)07037-8 10.1056/NEJMoa021778 10.1016/S0140-6736(04)16895-5 10.1056/NEJMoa0806359 10.1016/S0140-6736(14)61368-4 10.2337/dc09-0523 10.2337/dc17-1116 10.1111/dme.13091 10.1111/dme.13789 10.1016/S0140-6736(12)60525-X 10.2337/dc14-0407 10.1002/dmrr.3097 10.1016/j.metabol.2014.03.012 10.3945/jn.110.121533 10.2337/dci18-0007 10.1038/nature12828 10.1186/s12933-019-0977-z 10.1186/s12933-019-0892-3 10.1038/nm.2307 10.1172/JCI44442 10.1172/JCI64801 10.2337/db12-0495 10.1016/j.cmet.2012.01.024 10.1016/j.metabol.2019.04.001 10.1016/j.jchromb.2019.04.053 10.1373/clinchem.2014.228965 10.2337/dc14-0560 10.2337/dc19-2533 10.1016/j.isci 10.1016/j.metabol.2019.06.011 10.1007/BF00280883 10.1530/EJE-17-0883 10.1249/01.MSS.0000078924.61453.FB 10.1242/dmm.001180 10.1038/msb.2010.93 10.2307/2531595 10.1093/fampra/cmw031 10.2337/diacare.26.12.3230 10.1038/nutd.2017.21 10.2337/dc19-0100 10.3389/fphar.2015.00218 10.1007/s00439-012-1256-1 10.1371/journal.pone.0176209 10.1007/s00125-015-3520-0 10.1093/ije/dyh299
Cardiovascular Diabetology; Sevilla-González MDR, Merino J et. al.

Feb 28th, 2021 - Impaired fasting glucose (IFG) is a prevalent and potentially reversible intermediate stage leading to type 2 diabetes that increases risk for cardiometabolic complications. The identification of clinical and molecular factors associated with the ...

A lipid lover's guide to novel therapeutics for lipid and cardiovascular risk reduction.
https://doi.org/10.2217/fca-2020-0216
Future Cardiology; Hritani R, Hussain A et. al.

Feb 18th, 2021 - Lipids and lipoproteins are the target of many novel therapeutics and are an area with great potential for the prevention and treatment of cardiovascular disease (CVD). Reduction of low-density lipoprotein cholesterol has been the mainstay of redu...

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high card...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843090
American Heart Journal; Ambrosy AP, Malik UI et. al.

Jan 31st, 2021 - The MITIGATE study aims to evaluate the real-world clinical effectiveness of pre-treatment with icosapent ethyl (IPE), compared with usual care, on laboratory-confirmed viral upper respiratory infection (URI)-related morbidity and mortality in adu...

Achieving Optimal Medical Therapy: Insights From the ORBITA Trial.
https://doi.org/10.1161/JAHA.120.017381
Journal of the American Heart Association; Foley M, Rajkumar CA et. al.

Jan 26th, 2021 - Background In stable coronary artery disease, medications are used for 2 purposes: cardiovascular risk reduction and symptom improvement. In clinical trials and clinical practice, medication use is often not optimal. The ORBITA (Objective Randomis...

Effect of a diet intervention on cardiometabolic outcomes: Does race matter? A randomiz...
https://doi.org/10.1016/j.clnesp.2020.12.012
Clinical Nutrition ESPEN; Kahleova H, Rembert E et. al.

Jan 25th, 2021 - In the U.S., Blacks as a group have an earlier onset, greater severity, and earlier mortality from cardiovascular disease than their White peers. The aim of this study was to test whether Black and White individuals experience similar cardiovascul...

see more →

Guidelines  55 results

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545583
Journal of the American College of Cardiology; Das SR, Everett BM et. al.

Aug 10th, 2020 - 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.|2020|Das SR,Everett BM,Birtcher KK,Brown...

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
http://www.onlinejacc.org/content/early/2019/03/07/j.jacc.2019.03.010
Journal of the American College of Cardiology;

Mar 16th, 2019 - Although there has been substantial improvement in atherosclerotic cardiovascular disease (ASCVD) outcomes in recent decades, ASCVD remains the leading cause of morbidity and mortality globally (S1- 1–S1-3). In the United States, it is also the le...

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31942-1/fulltext

Feb 1st, 2019 - Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large sta...

Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events
https://jamanetwork.com/journals/jama/article-abstract/2721178
Zheng,S.,et al

Jan 21st, 2019 - Question: What is the association of aspirin use with cardiovascular events and bleeding events in individuals without cardiovascular disease? Findings: In this meta-analysis of 13 trials with 164 225 participants without cardiovascular disease, a...

Evidence of CV benefits of Mediterranean diet growing
https://www.healio.com/cardiology/chd-prevention/news/online/%7B51d6ca5b-5a70-4e7e-ae7b-84b411d0fd62%7D/evidence-of-cv-benefits-of-mediterranean-diet-growing

Jan 5th, 2019 - After the holidays, often as part of a New Year’s resolution, it is common for people to think about changing to a healthier diet. One option is the Mediterranean diet, which was recently named by U.S. News & World Report as the top overall diet, ...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  949 results

Clinical and metabolomic predictors of regression to normoglycemia in a population at i...
https://doi.org/10.1186/s12933-021-01246-1 10.1016/j.diabres.2018.02.023 10.1097/MCO.0000000000000307 10.1136/bmj.i5953 10.1056/NEJM199807233390404 10.1016/S0140-6736(10)60484-9 10.1016/S0140-6736(98)07037-8 10.1056/NEJMoa021778 10.1016/S0140-6736(04)16895-5 10.1056/NEJMoa0806359 10.1016/S0140-6736(14)61368-4 10.2337/dc09-0523 10.2337/dc17-1116 10.1111/dme.13091 10.1111/dme.13789 10.1016/S0140-6736(12)60525-X 10.2337/dc14-0407 10.1002/dmrr.3097 10.1016/j.metabol.2014.03.012 10.3945/jn.110.121533 10.2337/dci18-0007 10.1038/nature12828 10.1186/s12933-019-0977-z 10.1186/s12933-019-0892-3 10.1038/nm.2307 10.1172/JCI44442 10.1172/JCI64801 10.2337/db12-0495 10.1016/j.cmet.2012.01.024 10.1016/j.metabol.2019.04.001 10.1016/j.jchromb.2019.04.053 10.1373/clinchem.2014.228965 10.2337/dc14-0560 10.2337/dc19-2533 10.1016/j.isci 10.1016/j.metabol.2019.06.011 10.1007/BF00280883 10.1530/EJE-17-0883 10.1249/01.MSS.0000078924.61453.FB 10.1242/dmm.001180 10.1038/msb.2010.93 10.2307/2531595 10.1093/fampra/cmw031 10.2337/diacare.26.12.3230 10.1038/nutd.2017.21 10.2337/dc19-0100 10.3389/fphar.2015.00218 10.1007/s00439-012-1256-1 10.1371/journal.pone.0176209 10.1007/s00125-015-3520-0 10.1093/ije/dyh299
Cardiovascular Diabetology; Sevilla-González MDR, Merino J et. al.

Feb 28th, 2021 - Impaired fasting glucose (IFG) is a prevalent and potentially reversible intermediate stage leading to type 2 diabetes that increases risk for cardiometabolic complications. The identification of clinical and molecular factors associated with the ...

A lipid lover's guide to novel therapeutics for lipid and cardiovascular risk reduction.
https://doi.org/10.2217/fca-2020-0216
Future Cardiology; Hritani R, Hussain A et. al.

Feb 18th, 2021 - Lipids and lipoproteins are the target of many novel therapeutics and are an area with great potential for the prevention and treatment of cardiovascular disease (CVD). Reduction of low-density lipoprotein cholesterol has been the mainstay of redu...

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high card...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843090
American Heart Journal; Ambrosy AP, Malik UI et. al.

Jan 31st, 2021 - The MITIGATE study aims to evaluate the real-world clinical effectiveness of pre-treatment with icosapent ethyl (IPE), compared with usual care, on laboratory-confirmed viral upper respiratory infection (URI)-related morbidity and mortality in adu...

Achieving Optimal Medical Therapy: Insights From the ORBITA Trial.
https://doi.org/10.1161/JAHA.120.017381
Journal of the American Heart Association; Foley M, Rajkumar CA et. al.

Jan 26th, 2021 - Background In stable coronary artery disease, medications are used for 2 purposes: cardiovascular risk reduction and symptom improvement. In clinical trials and clinical practice, medication use is often not optimal. The ORBITA (Objective Randomis...

Effect of a diet intervention on cardiometabolic outcomes: Does race matter? A randomiz...
https://doi.org/10.1016/j.clnesp.2020.12.012
Clinical Nutrition ESPEN; Kahleova H, Rembert E et. al.

Jan 25th, 2021 - In the U.S., Blacks as a group have an earlier onset, greater severity, and earlier mortality from cardiovascular disease than their White peers. The aim of this study was to test whether Black and White individuals experience similar cardiovascul...

see more →

News  93 results

How Real-world Data Augments What We Know About SGLT-2 Inhibitors for Cardiovascular Risk Reduction
https://www.medscape.com/viewarticle/937947

Oct 11th, 2020 - Multiple clinical trials demonstrate the efficacy of sodium-glucose co-transporter-2 (SGLT-2) inhibitors to reduce cardiovascular events in persons with diabetes.[1,2,3,4] Use of these agents has been associated with consistent reductions in the c...

2020 ADA Standards: A 'New Concept' in Treating T2D
https://www.medscape.com/viewarticle/924308

Feb 27th, 2020 - This transcript has been edited for clarity. Today I'm going to continue my overview of the 2020 American Diabetes Association (ADA) Standards of Medical Care in Diabetes. Pharmacologic approaches to the management of glycemia in patients with typ...

New Vascepa Approval Opens Up Treatment to Millions
https://www.staging.medscape.com/viewarticle/922865

Dec 17th, 2019 - The newly approved US indication for icosapent ethyl (Vascepa, Amarin) is broadly in line with the entry criteria for the REDUCE-IT trial and includes a large high-risk primary prevention population, as well as those with established cardiovascula...

New Vascepa Approval Opens Up Treatment to Millions
https://www.medscape.com/viewarticle/922865

Dec 17th, 2019 - The newly approved US indication for icosapent ethyl (Vascepa, Amarin) is broadly in line with the entry criteria for the REDUCE-IT trial and includes a large high-risk primary prevention population, as well as those with established cardiovascula...

Icosapent ethyl approved for cardiovascular risk reduction
https://www.mdedge.com/emergencymedicine/article/214314/lipid-disorders/icosapent-ethyl-approved-cardiovascular-risk?channel=39313
Catherine Hackett

Dec 13th, 2019 - Icosapent ethyl (Vascepa) has gained an indication from the Food and Drug Administration for reduction of cardiovascular events in patients with high triglycerides who are at high risk for cardiovascular events. Olivier Le Moal/Getty Images It is.

see more →